Minerva Neurosciences

$3.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.74 (+27.31%) Today

+$0.06 (+1.74%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell NERV and other stocks, options, and ETFs commission-free!

About NERV

Minerva Neurosciences, Inc Common Stock, also called Minerva Neurosciences, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA. The listed name for NERV is Minerva Neurosciences, Inc Common Stock.

CEO

Rémy Henri Luthringer

Employees

Headquarters

Waltham, Massachusetts

Founded

2007

Market Cap

143.97M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

490.65K

High Today

$3.75

Low Today

$3.26

Open Price

$3.65

Volume

11.23M

52 Week High

$15.22

52 Week Low

$1.81

Collections

Analyst Ratings

83%

of 6 ratings

Buy

83%

Hold

17%

Sell

NERV Earnings

-$0.77

-$0.27

$0.23

$0.73

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 8, Pre-Market